Savara Newsroom

Wells Fargo Initiates Savara(SVRA.US) With Buy Rating, Announces Target Price $8

Moomoo NewsDec 20 13:31 ET · Ratings

Wells Fargo Initiates Coverage On Savara With Overweight Rating, Announces Price Target of $8

BenzingaDec 20 08:24 ET · Ratings

Savara Analyst Ratings

BenzingaDec 19 10:18 ET · Ratings

JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9

Moomoo NewsDec 19 05:31 ET · Ratings

Savara Positioned for Success: Buy Rating Boosted by Strong BLA Progress and Market Potential for Molbreevi

TipRanksDec 19 05:25 ET · Ratings

Savara Initiates Rolling Submission of BLA to FDA for MOLBREEVI

TipRanksDec 18 16:10 ET

Savara Initiates Rolling Submission Of Biologics License Application To FDA For MOLBREEVI In Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis

BenzingaDec 18 16:06 ET

Express News | Savara Inc - to Request Priority Review of Bla

ReutersDec 18 16:05 ET

Express News | Savara Inc - Expects to Complete Bla Submission by End of 1Q 2025

ReutersDec 18 16:05 ET

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (APAP)

BusinesswireDec 18 16:05 ET

Express News | Savara Initiates Rolling Submission of a Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

ReutersDec 18 16:05 ET

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

BusinesswireDec 17 16:05 ET

Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)

Yahoo FinanceNov 25 09:18 ET

Savara Announces New Employment Inducement Grant

BusinesswireNov 22 16:05 ET

Savara Announces Encore Presentation of Results From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the British Thoracic Society Winter Meeting 2024

BusinesswireNov 22 08:05 ET

Express News | Savara Announces Encore Presentation of Results From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the British Thoracic Society Winter Meeting 2024

ReutersNov 22 08:05 ET

Independent Director of Savara David Ramsay Buys 4.5% More Shares

Simply Wall StNov 21 05:06 ET

Insider Purchase: Director at $SVRA (SVRA) Buys 20,000 Shares

Quiver QuantitativeNov 20 08:00 ET

Savara Insider Bought Shares Worth $287,600, According to a Recent SEC Filing

MT NewswiresNov 18 12:37 ET

Savara Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 13 09:53 ET · Ratings